Skip to content

Role of Left Ventricular Pacing Site

Importance of Left Ventricular Pacing Site in Biventricular Resynchronization Therapy for Severe Heart Failure

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00221780
Enrollment
33
Registered
2005-09-22
Start date
2003-11-30
Completion date
2007-12-31
Last updated
2007-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiomyopathy, Dilated, Coronary Disease, Heart Failure

Keywords

Heart failure, Cardiomyopathy, dilated, Coronary disease, Cardiac Pacing, Artificial, Hemodynamics, Randomized Controlled Trials, Single-Blind Study

Brief summary

Cardiac resynchronization therapy has been shown to be effective in reducing symptoms and mortality in heart failure patients. However, very few is known about the importance of the left ventricular pacing site. We study in a random order 11 different left ventricular pacing sites and compare their hemodynamics using pressure-volume catheters. The consequences on the surface ECG are also assessed.

Detailed description

Background. Cardiac resynchronization therapy has been shown to be effective in reducing symptoms and mortality in heart failure patients. However, very few is known about the importance of the left ventricular pacing site. Design. Single-blind, monocentric, randomized cross-over study comparing 11 left ventricular pacing sites in a random order. Intervention. Left ventricular DDD pacing on 11 ventricular sites, prior to the implantation. At each pacing site, a control hemodynamics will be obtained in AAI pacing at the same pacing rate. At each pacing site, 2 AV delays, a short and a long one, will be assessed. Eligibility criteria. Patients referred for cardiac resynchronization therapy for heart failure Outcomes. Hemodynamic measures using pressure-volume catheters.

Interventions

DEVICEleft ventricular pacing

Sponsors

Ministry of Health, France
CollaboratorOTHER_GOV
University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Heart failure referred for cardiac resynchronization therapy * NYHA Class III or IV * Informed consent form signed

Exclusion criteria

* Hypertension not controlled by treatment * Coronary ischemia not controlled by treatment

Design outcomes

Primary

MeasureTime frame
Variation in left ventricular dp/dt max

Secondary

MeasureTime frame
pressures and volumes of the left ventricle
stroke work
surface ECG repolarisation

Countries

France

Contacts

Primary ContactPierre Jaïs, Dr
pierre.jais@chu-bordeaux.fr33 (0) 5 57 65 64 71

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026